Digital Pathology Podcast

• 174: How Do We Fix the Bias in Biomedical AI Podcast with Victor CEO and Founder of Omica.Ai

  Send us a textWhy are billions of people still invisible in genomic research—and what does that mean for the future of precision medicine?In this episode, I sit down with Victor Angel Mosti, founder and CEO of Omica.Ai, for one of the most insightful conversations I’ve recorded about data equity and building ethical, community-centered AI.Victor shares not only his personal cancer story but also the staggering truth: Hispanic and Latino populations make up less than 1% of genomic datasets. This underrepresentation isn’t just a data gap—it’s a clinical risk.We dive into disparities between healthcare systems, the promise of digital pathology as a low-cost entry point, the dangers of “parachute science,” and how Victor is building a living, ethical, transparent biobank through Omica. AI—built for true precision medicine rooted in community trust.Highlights with Timestamps[00:00–01:40] Personal cancer experiences and diagnostic uncertainty[01:40–06:50] Victor’s medical journey across Mexico and the U.S.[06:50–11:42] The digitization gap: empathy vs. tech[11:42–16:43] The “coffee diversity” metaphor for genomic diversity[16:43–19:34] Funding disparities & the biotech cold-start problem[19:34–25:44] Digital pathology as a gateway to precision medicine[25:44–31:44] Avoiding “parachute science” and building community-first research[31:44–36:05] The Nagoya Protocol and benefit-sharing[36:05–41:47] Omica.Ai’s work, goals, and clinical-embedded approach[41:47–49:36] Creating future-proof, embedded biobanks[49:36–53:35] Blockchain for transparency and patient trust[53:35–54:39] Victor’s call to action: collaborate, include, and stay humanResources from This EpisodeOmica.Ai – Community-driven precision medicine platformNagoya Protocol – Framework for equitable biological useKey InsightsCancer is personal—even for experts<1% representation of Latino genomes threatens clinical accuracyDigital pathology + AI can leapfrog infrastructure gapsEthical biobanking requires trust, transparency, and local benefitAvoiding “parachute science” is essentialGenetic diversity drives discovery—but only if we capture itBlockchain + dynamic consent = future of patient-centered dataSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

  --------  

  55:24

  --------

  55:24
• 173: AI and the Human Touch: Patient Safety, Prognosis & Voice Biomarkers

  Send us a textHow far can AI go in helping us diagnose disease—without losing the human judgment patients rely on?In this episode, I break down four studies shaping the future of digital pathology, oncology, and neurology. From spatial biology updates at SITC to voice-based Alzheimer’s detection, deep learning for sarcoma prognosis, and new guidelines for safe AI deployment, this week’s digest highlights where AI is making a real impact—and where caution still matters.Episode Highlights1️⃣ SITC Trends & Spatial Biology (00:00 → 07:40)I share key updates from SITC 2025, including the growing role of multiplex immunofluorescence (mIF) and the need for integrated staining-to-scanning workflows. I also preview new educational content and upcoming podcast guests in global AI research.2️⃣ Digital Neuropathology & Alzheimer’s (07:40 → 13:01)A major review confirms that digital neuropathology is now robust enough for large-scale Alzheimer’s studies—opening doors for computational tools to link histology with cognition.3️⃣ Patient Safety in AI (13:01 → 19:56)An Italian review underscores the foundations of trustworthy AI: dataset quality, transparency, oversight, and continuous validation. I discuss why “patient-centered AI” must remain our standard.4️⃣ Voice Biomarkers for Cognitive Decline (19:56 → 26:43)AI models analyzing short speech recordings are showing high accuracy for early Alzheimer’s detection. This could make future screening simple, noninvasive, and more accessible.5️⃣ Deep Learning for Sarcoma Prognosis (34:06 → 35:59)A multi-instance CNN outperforms FNCLCC grading by identifying prognostic patterns in tumor center and periphery regions, offering new insights into soft-tissue sarcoma biology.TakeawaysmIF is maturing quickly but needs standardized, end-to-end workflows.Digital neuropathology is ready for broader Alzheimer’s research.Safe AI requires multidisciplinary collaboration and rigorous validation.Voice biomarkers may become powerful tools for early cognitive assessment.Deep learning can refine prognosis and reveal hidden tumor patterns.ResourcesHamamatsu (MoxiePlex) • Biocare Medical (ONCORE Pro X) • SITC Programs • Recent publications on AI biomarkers and computational pathology.Thanks for listening—and for being part of this growing digital pathology community.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

  --------  

  29:40

  --------

  29:40
• 172: Why Structured Reporting Is the Future of Pathology | mTuitive on Workflow, Data & Compliance with Peter O'Toole

  Send us a textIf your pathology reports and other data could talk, what would they say about the future of precision medicine? The truth is, most labs already have the data—they’re just not having a conversation with it.In this episode, I talk with Peter O’Toole, President and Chief Software Architect at mTuitive. We recorded live at Pathology Visions and are covering the power of structured data and how it’s redefining the future of pathology reporting, AI, and clinical decision support.We explore how structured reporting evolved from checklists to intelligence, why data hygiene and workflow integration matter more than AI buzzwords, and how collaboration across companies like mTuitive is helping labs turn their reports into clinically actionable data.Highlights with Timestamps[00:00–05:40] Data as the new currency in pathology — Why structured data is the foundation for clinical, research, and trial insights.[05:40–10:30] AI & Large Language Models (LLMs) — What AI can (and can’t) do when your data isn’t structured.[10:30–19:25] AI workflow integration & voice recognition — How AI and structured reporting work together inside the LIS and IMS.[19:25–25:27] Overcoming resistance — Why pathologists initially resisted structured reports and how perceptions are shifting globally.[25:27–29:53] Decision support & beyond cancer — Expanding structured data to liver, skin, and even mental health pathology.[29:53–34:15] Collaboration as the catalyst — How partnerships create seamless ecosystems for pathology data.[34:15–37:03] Demo: Synoptic reporting in action — Real-time staging, automation, and compliance made easy.Resources from this EpisodemTuitive website: https://mtuitive.comCAP Synoptic Reporting Protocols – Standardized templates for structured pathology reports.Pathology Visions Conference 2025 – Event where this discussion took place.Key Takeaways✅ Structured reporting transforms pathology data from static text into actionable intelligence.✅ AI and LLMs complement structured data—but can’t replace its clinical readiness.✅ Clean data in = clean data out—data hygiene defines AI reliability and efficiency.✅ Workflow integration and user-friendly design drive real-world adoption.✅ Structured data unlocks clinical trials access, research potential, and decision support tools.✅ Collaboration is key to building the connected ecosystem pathology needs.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

  --------  

  37:45

  --------

  37:45
• 171: Real-World Digital Readiness: Turning Stains into Reliable Scans

  Send us a textIs your lab truly digitally ready—or just scanning slides?That’s the question I unpack in this live discussion from Day 2 of SITC’s 40th Anniversary Meeting, joined by David Anderson (Biocare Medical) and Don Ariyakumar (Hamamatsu Photonics). Together, we explore what digital readiness really means for multiplex immunofluorescence (mIF) and how to build reliable, reproducible workflows that scale from research to clinical settings.What We DiscussThe Discovery Funnel I open by situating mIF within the broader discovery funnel: researchers begin with hundreds of biomarkers, narrowing down to focused 4–10 marker panels where true clinical utility begins. But this only works if the lab is digitally prepared from the start—from slide prep to data capture.Defining Digital Readiness David Anderson reframes digital readiness as everything that happens before the scanner turns on:Reagent consistencyAntibody optimizationAutomationStandardized protocols All these elements ensure that downstream AI and image analysis tools work on clean, reproducible data instead of “fixing” noise later.The Pre-Analytical Foundation Don Ariyakumar emphasizes that scanning can’t fix variability. If staining or section quality isn’t standardized, digitization simply amplifies inconsistencies. True readiness starts at the bench, not the monitor.Integration Across Vendors We also talk about how interoperability between stainers, scanners, and spatial biology software is becoming essential. A disconnected workflow—mixing manual, unaligned steps—adds variables that no algorithm can fully normalize.Lessons from IHC’s Evolution The team draws parallels between multiplex IF today and IHC’s early days: once complex, now routine. Multiplex IF promises even richer tumor microenvironment insights, but only if standardization and automation catch up to the technology.Beyond the Funnel I revisit the “funnel” metaphor in a new light—arguing that as precision medicine grows, the bottom of the funnel broadens, not narrows. That means more tailored, smaller panels rather than one-size-fits-all assays, and a growing need for efficient, reproducible digital workflows.Key Takeaways“Digital readiness” starts before scanning — with chemistry, automation, and process control.Consistent pre-analytical quality = reproducible, AI-ready data.Interoperability between systems (like Biocare’s ONCORE Pro X and Hamamatsu’s MoxiePlex) accelerates workflow standardization.Multiplex IF is maturing quickly, just as IHC once did—on its way to becoming a cornerstone of precision pathology.Resources Mentioned🔹 Biocare Medical (Booth 717) — ONCORE Pro X™ open slide stainer automating mIF, IHC, FISH, and ISH protocols. 🌐 biocare.net🔹 Hamamatsu Photonics (Booth 415) — MoxiePlex™ multispectral imaging platform for high-plex spatial analysis. 🌐 hamamatsu.com🔹 Society for Immunotherapy of Cancer (SITC) — 40th Anniversary Meeting information and programs. 🌐 sitcancer.orgTimestamp Highlights00:00 — Welcome from SITCSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

  --------  

  22:58

  --------

  22:58
• 170: Inside SITC 2025: How Multiplex IF Is Changing Cancer Care

  Send us a textCan spatial biology and multiplex immunofluorescence truly transform how we understand cancer?I went live from the Society for Immunotherapy of Cancer (SITC) 2025 — the 40th Anniversary Meeting to explore how spatial biology, multiplex IF, and digital pathology are coming together to redefine cancer diagnostics, research, and precision medicine.This session kicked off a weekend of cutting-edge discussions with leaders from Hamamatsu (Booth 415) and Biocare Medical (Booth 717) — two companies helping laboratories around the world embrace digital transformation and spatial imaging in oncology.🧠 Episode Highlights & Key Moments0:00 — IntroductionI set the stage live from SITC 2025, explaining the goal of this series: to connect the science of multiplex imaging and spatial analysis with the practical needs of today’s cancer pathologists and researchers.~1:00 — What Is Multiplex Immunofluorescence (IF)?I explain how multiplex IF enables simultaneous detection of multiple biomarkers and immune cell types within a single tumor sample — giving us an unprecedented look at the tumor microenvironment and how cells interact.~2:30 — The Spatial Biology RevolutionWe talk about spatial biology as the “next frontier” beyond traditional histopathology — visualizing not just what is on the slide, but where it happens.~5:00 — Digital Pathology & AI ReadinessI discuss the importance of digital pathology systems for slide digitization and how AI-powered software is now helping identify biomarkers, quantify expression, and accelerate immunotherapy research.~7:30 — Featured Booths at SITC 2025Hamamatsu (Booth 415): High-end slide scanners and digital imaging solutions empowering pathology labs toward digital readiness.Biocare Medical (Booth 717): Showcasing the ONCORE Pro X — an open slide stainer that automates multiplex IF, IHC, FISH, and ISH protocols, plus smart software for optimizing complex staining processes.~9:00 — Real-World ImpactWe walk through clinical case examples where multiplex IF data guides immunotherapy decisions — helping clinicians stratify patients and tailor treatments more precisely.~12:00 — Getting StartedI share practical advice for researchers ready to adopt spatial biology or digital pathology, from workflow design to validation and staff training.~15:00 — Audience Q&ALive questions from the audience on implementation, data integration, and scaling multiplex workflows across research and clinical environments.~20:00 — Future DirectionsWe look ahead to how machine learning and spatial data integration will shape the next decade of immuno-oncology, including new SITC workshops on AI-driven tissue profiling.~24:00 — Wrap-Up & TakeawaysKey message: spatial biology is not just a trend — it’s the next layer of precision medicine. I invite everyone to visit Hamamatsu (Booth 415) and Biocare (Booth 717) and to stay tuned for the next livestream focused on multiplex IF in clinical settings.Resources Mentioned🔹 Hamamatsu Photonics (Booth 415)High-performance digital slide scanners and imaging systems.🌐 hamamatsu.com🔹 Biocare Medical (Booth 717)ONCORE Pro X — Open sliSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

  --------  

  22:50

  --------

  22:50

More Health & Wellness podcasts

Trending Health & Wellness podcasts

About Digital Pathology Podcast